



**Organometallic Rhodium(III) and Iridium(III)
Cyclopentadienyl Complexes with Curcumin and
Bisdemethoxycurcumin Co-ligands.**

Journal:	<i>Dalton Transactions</i>
Manuscript ID	DT-ART-08-2015-003037.R1
Article Type:	Paper
Date Submitted by the Author:	12-Oct-2015
Complete List of Authors:	Pettinari, Riccardo; University of Camerino, Marchetti, Fabio; University of Camerino, Chemical Sciences Pettinari, Claudio; University of Camerino, Dipartimento Scienze Chimiche Condello, Francesca; University of Camerino, School of Pharmacy Petrini, Agnese; University of Camerino Scopelliti, Rosario; Ecole Polytechnique Federale de Lausanne, Institut des Sciences et Ingénierie Chimiques; Riedel, Tina; Ecole polytechnique federale de Lausanne, Institut de chimie moleculaire et biologique Dyson, Paul; Ecole polytechnique federale de Lausanne, Institut de chimie moleculaire et biologique



ARTICLE

Organometallic Rhodium(III) and Iridium(III) Cyclopentadienyl Complexes with Curcumin and Bisdemethoxycurcumin Co-ligands.

Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/

Riccardo Pettinari,^{a*} Fabio Marchetti,^b Claudio Pettinari,^a Francesca Condello,^a Agnese Petri,^a Rosario Scopelliti,^c Tina Riedel^c and Paul J. Dyson.^{c*}

A series of half-sandwich cyclopentadienyl rhodium(III) and iridium(III) complexes of the type $[\text{Cp}^*\text{M}(\text{curc}/\text{bdcurc})\text{Cl}]$ and $[\text{Cp}^*\text{M}(\text{curc}/\text{bdcurc})(\text{PTA})][\text{SO}_3\text{CF}_3]$, in which Cp^* = pentamethylcyclopentadienyl, curcH = curcumin and bdcurcH = bisdemethoxycurcumin as OAO-chelating ligands, and PTA = 1,3,5-triaza-7-phosphaadamantane is described. The X-ray crystal structures of three of the complexes, i.e. $[\text{Cp}^*\text{Rh}(\text{curc})(\text{PTA})][\text{SO}_3\text{CF}_3]$ (**5**), $[\text{Cp}^*\text{Rh}(\text{bdcurc})(\text{PTA})][\text{SO}_3\text{CF}_3]$ (**6**) and $[\text{Cp}^*\text{Ir}(\text{bdcurc})(\text{PTA})][\text{SO}_3\text{CF}_3]$ (**8**), confirm the expected "piano-stool" geometry. With the exception of **5**, the complexes are stable under pseudo-physiological conditions and are moderately cytotoxic to human ovarian carcinoma (A2780 and A2780cisR) cells and also to non-tumorigenic human embryonic kidney (HEK293) cells, but lack the cancer cell selectivity observed for related arene ruthenium(II) complexes.

Introduction

Curcumin is a naturally occurring polyphenol derived from the rhizomes of turmeric (*Curcuma longa*).¹ Curcumin (curcH) is the major component of three curcuminoids that give turmeric its characteristic yellow color. The minor curcuminoid components are demethoxycurcumin (dcurcH) and bisdemethoxycurcumin (bdcurcH) in which one or both -OMe functionalities at the outer phenol rings are removed.

Curcumin displays potent activity in vitro and in animal studies, acting as an anti-proliferative, anti-metastatic and antiangiogenic agent.²⁻⁵ Numerous studies have also explored the antioxidant, anti-hepatotoxic, anti-hyperlipidemic, antiviral, and anti-Alzheimer's disease effects.^{6, 7} Despite the promising biological effects of curcumin at the preclinical and clinical levels its therapeutic applications are, however, restricted by poor solubility and rapid metabolism resulting in very low bioavailability following oral administration.⁸ One strategy used to improve the biological (drug-like) properties of curcumin, which avoids covalently modifying the compound,^{9, 10} is to coordinate it to metal complexes.¹¹⁻¹³

Ruthenium compounds have emerged, in recent years, as promising alternatives to platinum drugs by displaying specific

activities against different cancers and favourable toxicity and clearance properties.¹⁴⁻²¹ Previously, we have demonstrated that half-sandwich ruthenium-arene complexes with curcumin and bisdemethoxycurcumin and an ancillary chloride ligand show promising activity as anticancer agents.^{22, 23} We have also shown that replacement of chloride with 1,3,5-triaza-7-phosphaadamantane ligand (PTA) led the formation of RAPTA-type complexes with superior solubility properties and also superior cytotoxicities.²⁴ It was found that the presence or absence of peripheral methoxy groups in curcumin and the different arene rings do not strongly influence the biological activity whereas the PTA ligand appears to significantly improve the pharmacological properties of the curcumin-modified arene ruthenium(II) complexes.

Rhodium and iridium complexes have been explored for their anticancer properties with initial efforts being focused on Rh(I) and Ir(I) compounds with a square-planar geometry similar to that of cisplatin.^{25, 26} Recently, more stable cyclopentadienyl Rh(III) and Ir(III) complexes, with higher structural diversity and a higher coordination number (6 versus 4),^{27, 28} have been shown to have highly potent anticancer activity.²⁹⁻⁴⁰

Based on the highly promising pharmacological properties of the arene ruthenium(II) complexes incorporating curcumin and bisdemethoxycurcumin co-ligands, combined with the exciting developments on the anticancer properties of Rh(III) and Ir(III) organometallic compounds, we decided to integrate these two areas and prepare and evaluate some pentamethylcyclopentadienyl Rh(III) and Ir(III) compounds containing curcumin-based ligands and, in some cases, PTA. It should be noted that two curcumin complexes of Rh(III) and Ir(III) have been reported,⁴¹ but structural data and biological studies were not described.

^a School of Pharmacy, University of Camerino, via S. Agostino 1, 62032 Camerino MC, Italy. E-mail: riccardo.pettinari@unicam.it; Tel: +39-0737-632338.

^b School of Science and Technology, University of Camerino, via S. Agostino 1, 62032 Camerino MC, Italy.

^c Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology (EPFL), CH-1015 Lausanne, Switzerland. E-mail: paul.dyson@epfl.ch; Fax: +41-21-6939885; Tel: +41-21-6939854.


^d * Footnotes relating to the title and/or authors should appear here.

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

Results and discussion

Synthesis

The rhodium(III) and iridium(III) pentamethylcyclopentadienyl complexes (**1–4**) were prepared in high yield (78–93%) from the reaction of the appropriate dimer, $[\text{Cp}^*\text{MCl}_2]_2$ ($\text{M} = \text{Rh}$ or Ir , $\text{Cp}^* = \eta^5\text{-pentamethylcyclopentadienyl}$) with the appropriate pro-ligand and KOH in methanol (Scheme 1). Analytical and spectral data for **1** and **3** are in accordance with literature data.⁴¹




Scheme 1 Synthesis of **1–4**.

Complexes **1–4** are air stable and soluble in acetone, acetonitrile and DMSO and slightly soluble in alcohols. In addition, the curcumin complexes, **1** and **3**, are also soluble in chlorinated solvents. Such different solubility appears to be due to the different R' substituents of curcumin ligands (Scheme 1). The IR spectra of **1–4** show the typical $\nu(\text{C}=\text{O}, \text{C}=\text{C})$ bands of curc and bdcurc at lower wavenumbers than the corresponding bands in the free ligands as a consequence of coordination through both carbonyl arms to the metal. In the far-IR region, several absorptions were observed in the range 482–445 and 252–242 cm^{-1} . These may be assigned to $\nu(\text{M}-\text{O})$ and $\nu(\text{M}-\text{Cl})$ stretches, respectively.⁴²

NMR spectra of **1–4** corroborate the expected structures containing the bidentate curcumin- and bisdemethoxycurcumin- ligands. For example, a doublet is observed in the $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of the rhodium derivatives **1** and **2** around δ 95 ($J(^{103}\text{Rh}-^{13}\text{C}) \approx 6.9$ Hz), whereas in the spectra of iridium derivatives **3** and **4** a singlet is observed. The electrospray ionisation (ESI) mass spectra of **1–4** display peaks corresponding to the species $[\text{Cp}^*\text{M}(\text{curc}/\text{bdcurc})]^+$, in which the chloride ligand has dissociated.

The chloride ligand in **1–4** is readily replaced by the water-soluble phosphine 1,3,5-triaza-7-phosphaadamantane (PTA), by treatment of the complexes with AgSO_3CF_3 in methanol containing PTA, affording $[\text{Cp}^*\text{M}(\text{curc}/\text{bdcurc})(\text{PTA})][\text{SO}_3\text{CF}_3]$ ($\text{M} = \text{Rh}$ **5** and **6** and $\text{M} = \text{Ir}$ **7** and **8**), as depicted in Scheme 2. The substitution of the chloride ligand by PTA and the formation of an ionic compound were confirmed by the disappearance of the $\nu(\text{M}-\text{Cl})$ band in the IR spectra of **5–8**. Moreover, also a characteristic absorption pattern in the region 1000–1200 cm^{-1} , indicative of a non-coordinated O_3SCF_3^- anion, has been observed.⁴⁴ The ^1H NMR spectra of **5–8** in CD_3CN display the expected signals due to the coordinated

Cp^* , curc or bdcurc and PTA ligands. The resonances due to the PTA are observed at lower field with respect to those of uncoordinated PTA, thus confirming coordination to the metal center.⁴⁵




Scheme 2 Synthesis of **5–8**.

The ^{31}P NMR spectra of rhodium complexes **5** and **6** in CD_3CN display a doublet centered at ca. -34 ppm with a $^1J_{\text{P-Rh}}$ value of ca. 151 Hz, and the iridium derivatives **7** and **8** comprise a single resonance at -56 ppm, in a range typical of related compounds.^{46, 47}

The ESI mass spectra of **5–8** in acetonitrile show two main peak envelopes, that of highest relative intensity corresponding to the fragment $[\text{Cp}^*\text{M}(\text{curc}/\text{bdcurc})]^+$, upon dissociation of PTA, the other corresponding to the intact species $[\text{Cp}^*\text{M}(\text{curc}/\text{bdcurc})(\text{PTA})]^+$.

Complex **5** in water-DMSO (80–20%) solution is stable, its ^{31}P NMR spectra remaining unchanged after 96h. The stability of **5** was also determined under pseudo-pharmacological conditions in 5 mM NaCl solution (being a model for the low intracellular chloride concentration in cells) and in 100 mM NaCl solution (approximating to the higher chloride levels in blood). Solutions of the complexes ($c = 2.0$ mM) in aqueous NaCl ($c = 5$ mM or 100 mM in D_2O containing 20% of $[\text{D}_6]\text{DMSO}$) were prepared and maintained at 37 °C for 7 days. The decomposition of the complexes was monitored by ^1H and ^{31}P NMR spectroscopy.

The $^{31}\text{P}\{^1\text{H}\}$ spectrum of **5** displays a doublet at -36.0 ppm ($J_{\text{PRh}} = 155$ Hz), corresponding to the starting species, $[\text{Cp}^*\text{Rh}(\text{curc})(\text{PTA})]^+$ (**RhA**) (Scheme 3 and Figure 1).



Scheme 3 Decomposition of **5** (**RhA**) into $[\text{Cp}^*\text{Rh}(\text{PTA})_2\text{Cl}]^+$ (**RhB**), $[\text{Cp}^*\text{Rh}(\text{curc})\text{Cl}]^+$ (**RhC**), $[\text{Cp}^*\text{Rh}(\text{PTA})\text{Cl}_2]^+$ (**RhD**) and into curc, under pseudo-pharmacological conditions.

After 1 day, signals indicative of two new species are observed in both 5 and 100 mM aqueous NaCl solutions. The first

doublet in the range $-35.7/-36.0$ ppm ($J_{\text{PRh}} = 147$ Hz) corresponds to the $[\text{Cp}^*\text{Rh}(\text{PTA})_2\text{Cl}]^+$ (**RhB**) species, previously reported by Macchioni and co-workers,¹⁶ arising from the release of curc ligand and its replacement with a chloride and a second PTA from another $[\text{Cp}^*\text{Rh}(\text{curc})(\text{PTA})]^+$ species, which in turns likely affords a third neutral species of formula $[\text{Cp}^*\text{Rh}(\text{curc})\text{Cl}]$ (**RhC**). The second doublet in the range $-37.3/-37.4$ ppm ($J_{\text{PRh}} = 134$ Hz) corresponds to the $[\text{Cp}^*\text{Rh}(\text{PTA})\text{Cl}_2]$ (**RhD**) species.⁴⁸




Fig. 1. ^{31}P NMR spectra of **5** in 5 mM (left) and in 100 mM (right) aqueous NaCl solution.

After 96h an excess of PTA was added and, immediately, the resonance of $[\text{Cp}^*\text{Rh}(\text{PTA})_2\text{Cl}]^+$ (**RhD**) disappeared. Whereas, the intensity of $[\text{Cp}^*\text{Rh}(\text{PTA})_2\text{Cl}]^+$ (**RhB**) increased and the resonances of $[\text{Cp}^*\text{Rh}(\text{curc})(\text{PTA})]^+$ (**RhA**) reappeared, together with a new signal due to $[\text{Cp}^*\text{Rh}(\text{PTA})_3]^{+2}$ ($J_{\text{PRh}} = 120$ Hz).⁴⁸

The ^{31}P NMR spectrum of iridium compound **7** in water-DMSO (80-20%) solution showed immediately the formation of the hydrolysis products $[\text{Cp}^*\text{IrCl}_2(\text{PTA})]$ (**IrC**: -63.8 ppm) and $[\text{Cp}^*\text{Ir}(\text{OD})_2(\text{PTA})]^+$ (**IrB**: -65.7 ppm), in equilibrium with the starting species $[\text{Cp}^*\text{Ir}(\text{curc})(\text{PTA})]^+$ (**IrA**: -54.0 ppm). The nature of $[\text{Cp}^*\text{IrCl}_2(\text{PTA})]$ has been confirmed by adding an excess of NaCl (figure 2b), whereas the $[\text{Cp}^*\text{Ir}(\text{OD})_2(\text{PTA})]^+$ species has been hypothesized on the basis of a previous work by Peruzzini.⁴⁷

The difference in stability of iridium complexes with respect to rhodium analogues has been previously observed for complexes with other ligands such as poly(pyrazolyl)borates.^{49, 50}




Fig. 2. (a) ^{31}P NMR chemical shifts for **7** in D_2O -DMSO and (b) after addition of excess NaCl.

^{31}P NMR spectra of **5** in D_2O containing 20% DMSO were recorded at different pD values to determine the pK_a value of the coordinated PTA ligand. The chemical shift was plotted against pD (Figure 3) and the curve fitted using the Henderson-Hasselbach equation to give a pK_a of 3.36 ± 0.02 (0.44 is subtracted to account for the difference between the pH and pD).⁵¹




Fig. 3. A plot of the ^{31}P NMR chemical shift (δ) versus pD for **5**.

The solid-state structures of **5**, **6** and **8** were established by X-ray crystallography (see Experimental). Their structures are shown in Figure 4 and relevant bond distances and angles are given in the caption. The three metal complexes display the standard piano-stool geometry. Ligands show an almost planar geometry (the angles between the aromatic rings being 1.3° , 4.6° and 4.0° for compounds **5**, **6** and **8**, respectively), with a small twist around the central backbone (the calculated dihedral angles for the $-\text{C}=\text{C}(\text{O})-\text{C}=\text{C}-$ moieties varies from 1.7° in **5** to 8° in **8** to 8.8° in **6**). The bond distances and angles around the metal centers (see the caption to Figure 4) fall in the range of values found in the literature for similar compounds.¹⁹ Strong intermolecular hydrogen bonds are observed between the ligands and the anions (CF_3SO_3^-) [$\text{O}\cdots\text{O}$, $2.716(2)$ Å, $\angle\text{OHO}$, $156(3)^\circ$ in **5**; $\text{O}\cdots\text{O}$, $2.716(4)$ Å, $\angle\text{OHO}$, 167° in **6**; $\text{O}\cdots\text{O}$, $2.706(7)$ Å, $\angle\text{OHO}$, 167° in **8**] and between the ligands and the coordinated PTA of neighboring complexes [$\text{O}\cdots\text{N}$, $2.810(2)$ Å, $\angle\text{OHN}$, $155(3)^\circ$ in **5**; $\text{O}\cdots\text{N}$, $2.760(4)$ Å, $\angle\text{OHN}$, 163° in **6**; $\text{O}\cdots\text{N}$, $2.744(7)$ Å, $\angle\text{OHN}$, 163° in **8**]. Additional intramolecular $\text{OH}\cdots\text{O}$ interactions are observed in the crystal of **5**.




Fig. 4. Molecular structures of **5** (top), **6** (middle) and **8** (bottom). The counter-anion has been omitted for clarity. Bond distances (Å) and angles (°): [**5**] Rh1-O1, 2.107(1); Rh1-O2, 2.091(1); Rh1-P1, 2.314(1); Rh1- η^5 (centroid), 1.802(1). [**6**] Rh1-O1, 2.109(2); Rh1-O2, 2.089(2); Rh1-P1, 2.313(1); Rh1- η^5 (centroid), 1.808(2). [**8**] Ir1-O1, 2.117(4); Ir1-O2, 2.101(4); Ir1-P1, 2.299(2); Ir1- η^5 (centroid), 1.810(3).

The antiproliferative effects of **1-8** were investigated in two human ovarian cancer cell lines, A2780 and the cisplatin resistant A2780cisR cell line, as well as in non-tumorigenic human embryonic kidney (HEK293) cells. IC_{50} values for compounds **1-8** were determined after a 72 hour exposure period using the MTT assay (Table 1 and Experimental).

All the complexes were cytotoxic at moderate micromolar concentrations against both cancer cell lines with IC_{50} values in the 12–23 μM range for A2780 cells and in the 12–40 μM range for A2780cisR cells, indicating a lack of cross-resistance.

In HEK293 cells comparable IC_{50} values were obtained (14–32 μM) suggesting a lack of cancer cell selectivity.

Previously reported Rh(III) Cp* complexes containing maltol or allomaltol as O^O- chelating ligands were all inactive toward A549, CH1 and SW480 cell lines,⁵² whereas the lapachol complex shows good activity and selectivity toward the CH1 ovarian carcinoma cell line.⁵³ A cyclometalated rhodium(III) complex show lower⁵⁴ or comparable IC_{50} values toward A2780 cells.^{39, 55} Ir(III) Cp* complexes of formula $[(\eta^5\text{-Cp}^*)\text{Ir}(\text{L}^{\wedge}\text{L}')\text{Cl}]^{0/+}$ containing N^N- (phenanthroline, 2,2'-bipyridine, ethylenediamine), N^O- (picolinate) chelating ligands, are inactive on A2780 cells with IC_{50} values >100 μM ,^{31, 33} even with modified Cp*-type ligands.^{31, 56} However, varying the chelating ligand^{32, 40, 57-59} can lead to compounds with IC_{50} values considerably higher than cisplatin.

Cytotoxicity data for the A2780 cell line are comparable with the IC_{50} value obtained for $[(p\text{-cymene})\text{Ru}(\text{curc})\text{Cl}]$ in the HEK293 cell line, however, the rhodium(III) and iridium(III) complexes are 20-60 times less active than their corresponding ruthenium(II) analogues in the ovarian cancer cell lines.

The rhodium(III) and iridium(III) complexes with chloride **1-4** or PTA **5-8** co-ligands exhibit similar biological activities. This behaviour contrasts to that of the related ruthenium(II) complexes, in which the activity/selectivity of the PTA-containing complexes was superior to the chloride-based complexes.²² However, in keeping with the ruthenium(II) complexes, the nature of the curcuminoid ligand employed, i.e. curcumin and bisdemethoxycurcumin, plays little discernible role. It is not unreasonable to assume that following dissociation of the curcuminoid ligand the rhodium(III)/iridium(III) complexes interact with different biological targets to the arene ruthenium(II) derivatives, implying a different mechanism of action.

Table 1. Cytotoxicity of **1-8** following Incubation for 72 h on Human Ovarian Carcinoma A2780 and A2780R (Cisplatin-Resistant) and Non-tumorigenic Human Embryonic Kidney HEK293 Cell Lines.

Compound	A2780 (IC_{50} , μM)	A2780cisR (IC_{50} , μM)	HEK293 (IC_{50} , μM)
curcH	4.01 \pm 0.05	3.21 \pm 0.22	1.14 \pm 0.06
bdcurcH	4.60 \pm 0.10	4.61 \pm 0.22	2.22 \pm 0.14
1	14.9 \pm 2.1	12.3 \pm 0.3	13.7 \pm 0.3
2	20.0 \pm 2.0	18.1 \pm 0.2	31.8 \pm 0.2
3	23.2 \pm 0.8	14.1 \pm 2.5	16.3 \pm 0.7
4	20.7 \pm 5.6	23.6 \pm 2.3	26.1 \pm 2.9
5	12.5 \pm 0.5	16.0 \pm 3.0	17.2 \pm 4.8
6	14.7 \pm 2.2	17.7 \pm 0.2	19.0 \pm 4.0
7	23.2 \pm 2.3	39.4 \pm 9.4	29.4 \pm 3.9
8	21.0 \pm 1.0	33.3 \pm 3.6	15.6 \pm 1.4

Conclusions

Compared to platinum- or ruthenium-based anticancer agents, the study of the medicinal properties of rhodium and iridium complexes is poorly developed. Here, we described a series of novel pentamethylcyclopentadienyl rhodium(III) and iridium(III) complexes with curcumin or bisdemethoxycurcumin co-ligands and a chloride or PTA

ligand, these complexes being closely related to previously studied arene ruthenium(II) complexes.²⁴ Unlike related ruthenium(II) complexes with a PTA ligand, which display 100 times higher cytotoxicity towards cancer cells versus healthy cells, the compounds reported here are moderately cytotoxic to both human ovarian cancer cells and non-tumorigenic human embryonic kidney cells. Since it has been shown that all these compounds are able to release their curcuminoid ligands under physiological-like conditions it would suggest that the differences in activity between the pentamethylcyclopentadienyl M(III) (M = Rh/Ir) and arene ruthenium(II) compounds originate from the different metal fragments, which are known to have different binding preferences for certain biological targets.⁶²

Experimental section

General procedures

The dimers [Cp*MCl₂]₂ (M = Rh or Ir) were purchased from Aldrich. Curcumin and Bisdemethoxycurcumin were purchased from TCI Europe and were used as received. All other materials were obtained from commercial sources and were used as received. IR spectra were recorded from 4000 to 30 cm⁻¹ on a Perkin-Elmer Frontier Spectrometer FT-IR/FIR Instrument. ¹H and ¹³C NMR spectra were recorded on a 400 Mercury Plus Varian instrument operating at room temperature (400 MHz for ¹H and 100 MHz for ¹³C) relative to TMS. Positive and negative ion electrospray ionization mass spectra (ESI-MS) were obtained on a Series 1100 MSI detector HP spectrometer using methanol as the mobile phase. Solutions (3 mg/mL) analysis were prepared using reagent-grade methanol. Masses and intensities were compared to those calculated using IsoPro Isotopic Abundance Simulator, version 2.1.28. Melting points are uncorrected and were recorded on a STMP3 Stuart scientific instrument and on a capillary apparatus. Samples for microanalysis were dried in vacuo to constant weight (20 °C, ca. 0.1 Torr) and analysed on a Fisons Instruments 1108 CHNS-O elemental analyzer.

Synthesis of complexes 1-8

[Cp*Rh(curc)Cl] (1). Curcumin (curc, 184.2 mg, 0.5 mmol) was dissolved in methanol (20 mL) and KOH (28.05 mg, 0.5 mmol) was added. The mixture was stirred for 1 h at room temperature and then [Cp*RhCl₂]₂ (154.52 mg, 0.25 mmol) was added. The mixture was stirred for 24 h at room temperature and an orange precipitate formed which was filtered off and washed with 5 mL of diethylether (278.82 mg, 0.43 mmol, yield 87%). The residue was concentrated to ca. 2 mL and stored at 4 °C. Red crystals slowly afforded within 2 days. **1** is soluble in acetone, acetonitrile, chlorinated solvents, DMSO and slightly soluble in alcohols. M.p. 264–265 °C. Anal. Calcd. for C₃₁H₃₄ClO₆Rh: C, 58.09; H, 5.35. Found: C, 58.00; H, 5.26. IR (cm⁻¹): 3563w, 3157m, 1622m, 1590m v(C=C), 1505s, 472m, 454w, 242s v(Rh-Cl). ¹H NMR (CDCl₃, 293 K): δ, 1.69 (s, 15H, CH₃Cp*), 3.94 (s, 6H, OCH₃ of curc), 5.78 (s, 1H, C(1)H of curc), 6.51 (d, 2H, C(3, 3')H of curc, ³J_{trans} = 16 Hz), 6.90 (d, 2H, C(9, 9')H of curc, ³J_{aromH-H} = 9 Hz), 7.05 (m, 4H, C(6, 6')H and

C(10, 10')H of curc), 7.57 (d, 2H, C(4, 4')H of curc, ³J_{trans} = 16 Hz). ¹³C NMR (CDCl₃, 293 K): δ, 8.8 (s, CH₃Cp*), 56.1 (s, OCH₃ of curc), 94.7 (d, C_{Cp*}, J(¹⁰³Rh-¹³C) = 6.9 Hz), 102.2 (s, C(1) of curc), 109.4 (s, C(6, 6') of curc), 114.8 (s, C(9, 9') of curc), 122.5 (s, C(10, 10') of curc), 126.7 (s, C(5, 5') of curc), 128.8 (s, C(3, 3') of curc), 138.4 (s, C(4, 4') of curc), 146.8 (s, C(7, 7') of curc), 147.2 (s, C(8, 8') of curc), 178.7 (s, C(2, 2')=O of curc). ESI-MS (+) CH₃OH (m/z, relative intensity %): 605 [100] [Cp*Rh(curc)]⁺.

[Cp*Rh(bdc)Cl] (2). Compound **2** was prepared following a procedure similar to that reported for **1** by using bdc (270.12 mg, 0.46 mmol, yield 93%). **2** is soluble in acetone, acetonitrile, DMSO and slightly soluble in alcohols. M.p. 235–236 °C. Anal. Calcd. for C₂₉H₃₀ClO₄Rh: C, 59.96; H, 5.21. Found: C, 59.84; H, 5.16. IR (cm⁻¹): 3165br, 1618sh, 1599m v(C=C), 1492s, 478m, 450w, 244s v(Rh-Cl). ¹H NMR (CD₃CN, 293 K): δ, 1.63 (s, 15H, CH₃Cp*), 5.94 (s, 1H, C(1)H of bdc), 6.65 (d, 2H, C(3, 3')H of bdc, ³J_{trans} = 16 Hz), 6.88 (m, 4H, C(7, 7')H and C(9, 9')H of bdc), 7.46 (s, 2H, OH of bdc), 7.55 (m, 4H, C(6, 6')H and C(10, 10')H of bdc), 7.62 (d, 2H, C(4, 4')H of curc, ³J_{trans} = 16 Hz). ¹³C NMR (CD₃CN, 293 K): δ, 9.4 (s, CH₃Cp*), 95.5 (d, C_{Cp*}, J(¹⁰³Rh-¹³C) = 7.0 Hz), 102.3 (s, C(1) of bdc), 116.8 (s, C(7, 7') and C(9, 9') of bdc), 122.4 (s, C(6, 6') and (s, C(10, 10') of bdc), 126.7 (s, C(5, 5') of bdc), 131.2 (s, C(4, 4') of bdc), 141.1 (s, C(3, 3') of bdc), 146.8 (s, C(8, 8') of bdc), 178.7 (s, C(2, 2')=O of bdc). ESI-MS (+) CH₃CN (m/z, relative intensity %): 545 [100] [Cp*Rh(bdc)]⁺.

[Cp*Ir(curc)Cl] (3). Compound **3** was prepared following a procedure similar to that reported for **1** by using [Cp*IrCl₂]₂ (284.8 mg, 0.39 mmol, yield 78%). **3** is soluble in acetone, acetonitrile, chlorinated solvents, DMSO and slightly soluble in alcohols. M.p. 210–212 °C. Anal. Calcd. for C₃₁H₃₄ClO₆Ir: C, 50.99; H, 4.69. Found: C, 50.74; H, 4.62. IR (cm⁻¹): 3544w, 3270m, 1621m, 1586m v(C=C), 1504s, 474m, 461w, 245s v(Ir-Cl). ¹H NMR (CDCl₃, 293 K): δ, 1.66 (s, 15H, CH₃Cp*), 3.93 (s, 6H, OCH₃ of curc), 5.50 (s, 1H, C(1)H of curc), 6.45 (d, 2H, C(3, 3')H of curc, ³J_{trans} = 16 Hz), 6.89 (d, 2H, C(9, 9')H of curc, ³J_{aromH-H} = 8 Hz), 7.05 (m, 4H, C(6, 6')H and C(10, 10')H of curc), 7.55 (d, 2H, C(4, 4')H of curc, ³J_{trans} = 16 Hz). ¹³C NMR (CDCl₃, 293 K): δ, 9.0 (s, CH₃Cp*), 56.2 (s, OCH₃ of curc), 83.8 (s, C_{Cp*}), 103.3 (s, C(1) of curc), 109.3 (s, C(6, 6') of curc), 114.9 (s, C(9, 9') of curc), 122.5 (s, C(10, 10') of curc), 126.3 (s, C(5, 5') of curc), 128.9 (s, C(3, 3') of curc), 138.3 (s, C(4, 4') of curc), 147.0 (s, C(7, 7') of curc), 147.2 (s, C(8, 8') of curc), 176.5 (s, C(2, 2')=O of curc). ESI-MS (+) CH₃OH (m/z, relative intensity %): 695 [100] [Cp*Ir(curc)]⁺.

[Cp*Ir(bdc)Cl] (4). Compound **4** was prepared following a procedure similar to that reported for **2** by using [Cp*IrCl₂]₂ (298.25 mg, 0.44 mmol, yield 89%). **4** is soluble in alcohols, acetone, acetonitrile, DMSO and slightly soluble in chlorinated solvents. M.p. 230–232 °C. Anal. Calcd. for C₂₉H₃₀ClIrO₄: C, 51.97; H, 4.51. Found: C, 51.84; H, 4.48. IR (cm⁻¹): 3214w, 1621sh, 1598m v(C=C), 1493s, 1269s, 1158s, 482m, 445w, 252s v(Ir-Cl). ¹H NMR (CD₃CN, 293 K): δ, 1.63 (s, 15H, CH₃Cp*), 5.51 (s, 1H, C(1)H of bdc), 6.57 (d, 2H, C(3, 3')H of bdc, ³J_{trans} = 16 Hz), 6.87 (m, 4H, C(7, 7')H and C(9, 9')H of bdc), 7.37 (s, 2H, OH of bdc), 7.55 (m, 4H, C(6, 6')H and C(10, 10')H of bdc), 7.61 (m, 2H, C(4, 4')H of bdc). ¹³C NMR

(CD₃CN, 293 K): δ , 8.9 (s, CH₃Cp⁺), 92.7 (s, Cp⁺), 101.6 (s, C(1) of bdc_{curc}), 116.6 (s, C(7, 7') and C(9, 9') of bdc_{curc}), 121.4 (s, C(6, 6') and C(10, 10') of bdc_{curc}), 126.5 (s, C(5, 5') of bdc_{curc}), 131.0 (s, C(4, 4') of bdc_{curc}), 141.0 (s, C(3, 3') of bdc_{curc}), 160.5 (s, C(8, 8') of bdc_{curc}), 183.8 (s, C(2, 2')=O of bdc_{curc}). ESI-MS (+) CH₃CN (m/z, relative intensity %): 635 [100] [Cp*Ir(bdc_{curc})]⁺.

[Cp*Rh(curc)(PTA)][SO₃CF₃] (5). AgSO₃CF₃ (64 mg, 0.25 mmol) was added to a solution of **1** (160 mg, 0.25 mmol) in acetonitrile. The reaction mixture was stirred for 1 h and filtered to remove AgCl. PTA was added and the reaction mixture was carried out for 24 h at room temperature. The solvent was removed under reduced pressure and methanol and diethyl ether (20 mL) was added. The mixture was left at 4 °C until an orange precipitate formed. The orange crystalline powder was recovered by filtration and air-dried (154.9 mg, 0.169 mmol, yield 68%) and it was identified as **5**. It is soluble in alcohols, acetone, acetonitrile, DMSO and slightly soluble in chlorinated solvents and water. M.p. 253–254 °C. Anal. Calcd. for C₃₈H₄₆F₃N₃O₉PrHS: C, 50.06; H, 5.09; N, 4.61. Found: C, 50.00; H, 5.01; N, 4.55. IR (cm⁻¹): 3258w, 2925w, 1621sh, 1601m, 1583m v(C=C), 1496s, 1270s, 1148s, 1029s v(SO₃CF₃), 570m v(Rh-P), 472m, 454w, 421w v(Rh-P). ¹H NMR (CD₃CN, 293 K): δ , 1.68 (d, 15H, CH₃Cp⁺, J_{HP} = 3.4 Hz), 3.94 (s, 6H, OCH₃ of curc), 4.17 (s, 6H, NCH₂N, PTA), 4.49 (s, 6H, PCH₂N, PTA), 5.65 (s, 1H, C(1)H of curc), 6.76 (d, 2H, C(3, 3')H of curc, ³J_{trans} = 16 Hz), 6.89 (d, 2H, C(9, 9')H of curc, ³J_{aromH-H} = 8 Hz), 6.95 (sbr, 2H, OH of curc), 7.16 (dd, 2H, C(10, 10')H of curc, ³J_{aromH-H} = 8 Hz), 7.28 (s, 2H, C(6, 6')H of curc), 7.61 (d, 2H, C(4, 4')H of curc, ³J_{trans} = 16 Hz). ¹³C NMR (CD₃CN, 293 K): δ , 7.2 (s, CH₃Cp⁺), 47.8 (d, NCH₂P, PTA, J_{CP} = 11.1 Hz), 54.8 (s, OCH₃ of curc), 71.3 (d, NCH₂N, PTA, J_{CP} = 6.9 Hz), 97.9 (d, Cp⁺, J(¹⁰³Rh-¹³C) = 6.8 Hz), 102.7 (s, C(1) of curc), 109.5 (s, C(6, 6') of curc), 114.0 (s, C(9, 9') of curc), 121.8 (s, C(10, 10') of curc), 124.4 (s, C(5, 5') of curc), 126.9 (s, C(3, 3') of curc), 139.0 (s, C(4, 4') of curc), 146.7 (s, C(7, 7') of curc), 147.4 (s, C(8, 8') of curc), 179.2 (s, C(2, 2')=O of curc). ³¹P NMR (CD₃CN, 293 K): δ = -34.9 (d, J_{PRh} = 151 Hz, PTA). ESI-MS (+) CH₃CN (m/z, relative intensity %): 605 [100] [Cp*Rh(curc)]⁺, 762 [10] [Cp*Rh(curc)(PTA)]⁺.

[(Cp*)Rh(bdc_{curc})(PTA)][SO₃CF₃] (6). Compound **6** was prepared following a procedure similar to that reported for **5** by using precursor **2** (129.8 mg, 0.15 mmol, yield 61%). **6** is soluble in alcohols, acetone, acetonitrile, DMSO, chlorinated solvents and slightly soluble in water. M.p. 237–239 °C. Anal. Calcd. for C₃₆H₄₂F₃N₃O₇PrHS: C, 50.77; H, 4.97; N, 4.93. Found: C, 50.68; H, 4.86; N, 4.82. IR (cm⁻¹): 3157br, 1617sh, 1602m, 1588m v(C=C), 1493s, 1277s, 1160s, 1025s v(SO₃CF₃), 580m, 571m v(Rh-P), 476s, 450w, 346w v(Rh-P). ¹H NMR (CD₃CN, 293 K): δ , 1.67 (d, 15H, CH₃Cp⁺, J_{HP} = 3.4 Hz), 4.16 (s, 6H, NCH₂N, PTA), 4.48 (s, 6H, PCH₂N, PTA), 5.65 (s, 1H, C(1)H of bdc_{curc}), 6.71 (d, 2H, C(3, 3')H of bdc_{curc}, ³J_{trans} = 16 Hz), 6.88 (m, 4H, C(7, 7')H and C(9, 9')H of bdc_{curc}), 7.40 (s, 2H, OH of bdc_{curc}), 7.55 (m, 4H, C(6, 6')H and C(10, 10')H of bdc_{curc}), 7.62 (d, 2H, C(4, 4')H of bdc_{curc}, ³J_{trans} = 16 Hz). ¹³C NMR (CD₃CN, 293 K): δ , 8.5 (s, CH₃Cp⁺), 48.8 (d, NCH₂P, PTA, J_{CP} = 9.9 Hz), 72.5 (d, NCH₂N, PTA, J_{CP} = 11.1 Hz), 91.6 (s, Cp⁺) (d, Cp⁺, J(¹⁰³Rh-¹³C) = 7.0 Hz), 104.0 (s, C(1) of bdc_{curc}), 116.1 (s, C(7, 7') and C(9, 9') of bdc_{curc}), 125.4 (s, C(6, 6') and C(10, 10') of bdc_{curc}), 127.6 (s,

C(5, 5') of bdc_{curc}), 130.2 (s, C(4, 4') of bdc_{curc}), 139.9 (s, C(3, 3') of bdc_{curc}), 159.8 (s, C(8, 8') of bdc_{curc}), 178.4 (s, C(2, 2')=O of bdc_{curc}). ³¹P NMR (CD₃CN, 293 K): δ = -34.9 (d, J_{PRh} = 151 Hz, PTA). ESI-MS (+) CH₃CN (m/z, relative intensity %): 545 [100] [Cp*Rh(bdc_{curc})]⁺, 702 [10] [Cp*Rh(bdc_{curc})(PTA)]⁺.

[Cp*Ir(curc)(PTA)][SO₃CF₃] (7). Compound **7** was prepared following a procedure similar to that reported for **5** by using precursor **3** (157.66 mg, 0.15 mmol, yield 63%). **7** is soluble in alcohols, acetone, acetonitrile, DMSO and slightly soluble in chlorinated solvents and water. M.p. 227–229 °C. Anal. Calcd. for C₃₈H₄₆F₃IrN₃O₉PS: C, 45.59; H, 4.63; N, 4.20. Found: C, 45.50; H, 4.57; N, 4.14. IR (cm⁻¹): 2924br, 1613sh, 1599m, 1584m v(C=C), 1493s, 1270s, 1149s, 1028s v(SO₃CF₃), 575m v(Ir-P), 472m, 453w, 390w v(Ir-P). ¹H NMR (CD₃CN, 293 K): δ , 1.70 (d, 15H, CH₃Cp⁺, J_{HP} = 1.9 Hz), 3.94 (s, 6H, OCH₃ of curc), 4.16 (s, 6H, NCH₂N, PTA), 4.48 (m, 6H, PCH₂N, PTA), 5.71 (s, 1H, C(1)H of curc), 6.69 (d, 2H, C(3, 3')H of curc, ³J_{trans} = 16 Hz), 6.89 (d, 2H, C(9, 9')H of curc, ³J_{aromH-H} = 8 Hz), 7.04 (s, 2H, OH of curc), 7.18 (dd, 2H, C(10, 10')H of curc, ³J_{aromH-H} = 8 Hz), 7.30 (s, 2H, C(6, 6')H of curc), 7.63 (d, 2H, C(4, 4')H of curc, ³J_{trans} = 16 Hz). ¹³C NMR (CDCl₃, 293 K): δ , 9.4 (s, CH₃Cp⁺), 49.4 (d, PCH₂N, PTA, J_{CP} = 18.8 Hz), 57.1 (s, OCH₃ of curc), 73.6 (d, NCH₂N, PTA, J_{CP} = 7.1 Hz), 93.5 (s, Cp⁺), 105.9 (s, C(1) of curc), 111.7 (C(6, 6') of curc), 116.4 (C(9, 9') of curc), 124.1 (C(10, 10') of curc), 125.7 (C(5, 5') of curc), 129.2 (C(3, 3') of curc), 141.4 (C(4, 4') of curc), 149.0 (C(7, 7') of curc), 149.7 (C(8, 8') of curc), 179.5 (C(2, 2')=O of curc). ³¹P NMR (CD₃CN, 293 K): δ = -56.1 (s, PTA). ESI-MS (+) CH₃CN (m/z, relative intensity %): 695.2 [100] [Cp*Ir(curc)]⁺, 852 [30] [Cp*Ir(curc)(PTA)]⁺.

[Cp*Ir(bdc_{curc})(PTA)][SO₃CF₃] (8). Compound **8** was prepared following a procedure similar to that reported for **5** by using precursor **4** (152.91 mg, 0.16 mmol, yield 65%). **8** is soluble in alcohols, acetone, acetonitrile and DMSO. M.p. 249–251 °C. Anal. Calcd. for C₃₆H₄₂F₃IrN₃O₇PS: C, 45.95; H, 4.50; N, 4.47. Found: C, 45.83; H, 4.44; N, 4.41. IR (cm⁻¹): 3155br, 1615sh, 1602m, 1586m v(C=C), 1491s, 1278s, 1160s, 1025s v(SO₃CF₃), 600m, 577m v(Ir-P), 482s, 456w, 346w v(Ir-P). ¹H NMR (CD₃CN, 293 K): δ , 1.69 (d, 15H, CH₃Cp⁺, J_{HP} = 2.0 Hz), 4.16 (s, 6H, NCH₂N, pta), 4.48 (m, 6H, PCH₂N, pta), 5.71 (s, 1H, C(1)H of bdc_{curc}), 6.63 (d, 2H, C(3, 3')H of bdc_{curc}, ³J_{trans} = 16 Hz), 6.88 (m, 4H, C(7, 7')H and C(9, 9')H of bdc_{curc}), 7.44 (s, 2H, OH of bdc_{curc}), 7.57 (m, 4H, C(6, 6')H and C(10, 10')H of bdc_{curc}), 7.64 (d, 2H, C(4, 4')H of bdc_{curc}, ³J_{trans} = 16 Hz). ¹³C NMR (CD₃CN, 293 K): δ , 8.5 (s, CH₃Cp⁺), 48.1 (d, PCH₂N, PTA, J_{CP} = 18.4 Hz), 72.5 (d, NCH₂N, PTA, J_{CP} = 7.7 Hz), 92.4 (s, Cp⁺), 105.0 (s, C(1) of bdc_{curc}), 116.2 (s, C(7, 7') and C(9, 9') of bdc_{curc}), 124.4 (s, C(6, 6') and C(10, 10') of bdc_{curc}), 127.7 (s, C(5, 5') of bdc_{curc}), 130.2 (s, C(4, 4') of bdc_{curc}), 140.1 (s, C(3, 3') of bdc_{curc}), 159.2 (s, C(8, 8') of bdc_{curc}), 178.4 (s, C(2, 2')=O of bdc_{curc}). ³¹P NMR (CD₃CN, 293 K): δ = -56.3 (s, PTA). ESI-MS (+) CH₃CN (m/z, relative intensity %): 635 [100] [Cp*Ir(bdc_{curc})]⁺, 792 [20] [Cp*Ir(bdc_{curc})(PTA)]⁺.

X-ray crystal structure determinations

Diffraction data were measured at low temperature [100(2) K] using Mo K_α radiation on a Bruker APEX II CCD diffractometer equipped with a kappa geometry goniometer. The datasets

were reduced by *EvaICCD*⁶³ and then corrected for absorption.⁶⁴ The solutions and refinements were performed by *SHELX*.⁶⁵ The crystal structures were refined using full-matrix least-squares based on F^2 with all non hydrogen atoms anisotropically defined. Hydrogen atoms were placed in calculated positions by means of the “riding” model. Disorder problems dealing with the CF_3SO_3^- were encountered during the last stages of refinement and treated by the split model (SADI and SIMU cards were applied to retain a reasonable geometry and acceptable ADP).

Cell culture and inhibition of cell growth

The human A2780 and A2780cisR ovarian carcinoma and HEK (human embryonic kidney) cells were obtained from the European Collection of Cell Cultures (Salisbury, U.K.). A2780 and A2780cisR cells were grown routinely in RPMI-1640 medium, while HEK cells were grown in DMEM medium, with 10% fetal bovine serum (FBS) and 1% antibiotics at 37°C and 5% CO_2 . Cytotoxicity was determined using the MTT assay (MTT = 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium-bromide). Cells were seeded in 96-well plates as monolayers with 100 μL of cell suspension (approximately 5000 cells) per well and pre-incubated for 24 h in medium supplemented with 10% FBS. Compounds were prepared as DMSO solutions and then dissolved in the culture medium and serially diluted to the appropriate concentration, to give a final DMSO concentration of 0.5%. 100 μL of the drug solution was added to each well, and the plates were incubated for another 72 h. Subsequently, MTT (5 mg/mL solution) was added to the cells and the plates were incubated for a further 2 h. The culture medium was aspirated, and the purple formazan crystals formed by the mitochondrial dehydrogenase activity of vital cells were dissolved in DMSO. The optical density, directly proportional to the number of surviving cells, was quantified at 590 nm using a multiwell plate reader, and the fraction of surviving cells was calculated from the absorbance of untreated control cells. Evaluation is based on means from at least two independent experiments, each comprising triplicates per concentration level.

Determination of pK_a values

The pH values of NMR samples in D_2O were measured at 298 K, directly in the NMR tube, using a 713 pH meter (Metrohm) equipped with an electrode calibrated with buffer solutions at pH values of 4, 7, and 9. The pH values were adjusted with dilute HNO_3 and NaOH . The pH titration curves were fitted to the Henderson–Hasselbalch equation using the program Matlab (MathWorks Software) with the assumption that the observed chemical shifts are weighted averages according to the populations of the protonated and deprotonated species. The resonance frequencies change smoothly with pH between the chemical shifts of the charged form HA^+ , stable in acidic solution, and those of the neutral, deprotonated form A, which is present at a high pH. At any pH, the observed chemical shift is a weighted average (δ_{av}) of the two extreme values $\delta(\text{HA}^+)$ and $\delta(\text{A})$

$$\delta_{\text{av}} = \frac{\delta(\text{HA}^+)[\text{HA}^+] + \delta(\text{A})[\text{A}]}{[\text{HA}^+] + [\text{A}]}$$

The midpoint of the titration occurs when the concentrations of the acid and its conjugate base are equal: $[\text{HA}^+] = [\text{A}]$, that is, when the pH equals the pK_a of the compound. The pH at the midpoint of the curve is corrected by subtracting 0.44 to the pD values since the measurements were made in D_2O .⁶⁶

Acknowledgements

This work was financially supported by the University of Camerino (Fondo di Ateneo per la Ricerca 2011–2012), by MIUR (PRIN 2010–2011; 2010BNZ3F2) and by COST (CM 1302, European Network on Smart Inorganic Polymers).

References

1. B. B. Aggarwal, C. Sundaram, N. Malani and H. Ichikawa, *Journal*, 2007, **595**, 1-75.
2. A. K. Renfrew, N. S. Bryce and T. W. Hambley, *Chem. Sci.*, 2013, **4**, 3731-3739.
3. S. Banerjee, P. Prasad, A. Hussain, I. Khan, P. Kondaiah and A. R. Chakravarty, *Chem. Commun.*, 2012, **48**, 7702-7704.
4. M. Sagnou, D. Benaki, C. Triantis, T. Tsotakos, V. Psycharis, C. P. Raptopoulou, I. Pirmettis, M. Papadopoulos and M. Pelecanou, *Inorganic Chemistry*, 2011, **50**, 1295-1303.
5. G. Bar-Sela, R. Epelbaum and M. Schaffer, *Curr. Med. Chem.*, 2010, **17**, 190-197.
6. R. Waranyoupalin, S. Wongnawa, M. Wongnawa, C. Pakawatchai, P. Panichayupakaranant and P. Sherdshoopongse, *Cent. Eur. J. Chem.*, 2009, **7**, 388-394.
7. A. Goel, A. B. Kunnumakkara and B. B. Aggarwal, *Biochem. Pharmacol.*, 2008, **75**, 787-809.
8. P. Anand, A. B. Kunnumakkara, R. A. Newman and B. B. Aggarwal, *Mol. Pharm.*, 2007, **4**, 807-818.
9. A. Arezki, G. G. Chabot, L. Quentin, D. Scherman, G. Jaouen and E. Brulé, *MedChemComm*, 2011, **2**, 190-195.
10. A. Arezki, E. Brulé and G. Jaouen, *Organometallics*, 2009, **28**, 1606-1609.
11. S. Wanninger, V. Lorenz, A. Subhan and F. T. Edelmann, *Chem. Soc. Rev.*, 2015, **44**, 4986-5002.
12. A. Valentini, F. Conforti, A. Crispini, A. De Martino, R. Condello, C. Stelitano, G. Rotilio, M. Ghedini, G. Federici, S. Bernardini and D. Pucci, *J. Med. Chem.*, 2009, **52**, 484-491.
13. B. Balaji, B. Balakrishnan, S. Perumalla, A. A. Karande and A. R. Chakravarty, *Eur. J. Med. Chem.*, 2014, **85**, 458-467.
14. S. K. Singh and D. S. Pandey, *RSC Adv.*, 2014, **4**, 1819-1840.
15. G. Sava, A. Bergamo and P. J. Dyson, *Dalton Trans.*, 2011, **40**, 9069-9075.
16. E. Meggers, *Angew. Chem. Int. Ed.*, 2011, **50**, 2442-2448.
17. G. S. Smith and B. Therrien, *Dalton Trans.*, 2011, **40**, 10793-10800.
18. G. Gasser, I. Ott and N. Metzler-Nolte, *J. Med. Chem.*, 2011, **54**, 3-25.
19. A. L. Noffke, A. Habtemariam, A. M. Pizarro and P. J. Sadler, *Chem. Commun.*, 2012, **48**, 5219-5246.

20. N. P. E. Barry and P. J. Sadler, *Chem. Commun.*, 2013, **49**, 5106-5131.
21. C. G. Hartinger, M. Groessl, S. M. Meier, A. Casini and P. J. Dyson, *Chem. Soc. Rev.*, 2013, **42**, 6186-6199.
22. F. Caruso, M. Rossi, A. Benson, C. Opazo, D. Freedman, E. Monti, M. B. Gariboldi, J. Shaulky, F. Marchetti, R. Pettinari and C. Pettinari, *J. Med. Chem.*, 2012, **55**, 1072-1081.
23. L. Bonfili, R. Pettinari, M. Cuccioloni, V. Cekarini, M. Mozzicafreddo, M. Angeletti, G. Lupidi, F. Marchetti, C. Pettinari and A. M. Eleuteri, *ChemMedChem*, 2012, **7**, 2010-2020.
24. R. Pettinari, F. Marchetti, F. Condello, C. Pettinari, G. Lupidi, R. Scopelliti, S. Mukhopadhyay, T. Riedel and P. J. Dyson, *Organometallics*, 2014, **33**, 3709-3715.
25. T. Giraldi, G. Sava, G. Mestroni, G. Zassinovich and D. Stolfi, *Chem.-Biol. Interact.*, 1978, **22**, 231-238.
26. G. Sava, S. Zorzet, L. Perissin, G. Mestroni, G. Zassinovich and A. Bontempi, *Inorg. Chim. Acta*, 1987, **137**, 69-71.
27. C. Pettinari, R. Pettinari, M. Fianchini, F. Marchetti, B. W. Skelton and A. H. White, *Inorganic Chemistry*, 2005, **44**, 7933-7942.
28. C. Pettinari, R. Pettinari, F. Marchetti, A. Macchioni, D. Zuccaccia, B. W. Skelton and A. H. White, *Inorganic Chemistry*, 2007, **46**, 896-906.
29. Z. Liu and P. J. Sadler, *Acc. Chem. Res.*, 2014, **47**, 1174-1185.
30. M. Gras, B. Therrien, G. Süß-Fink, A. Casini, F. Edefe and P. J. Dyson, *J. Organomet. Chem.*, 2010, **695**, 1119-1125.
31. Z. Liu, A. Habtemariam, A. M. Pizarro, G. J. Clarkson and P. J. Sadler, *Organometallics*, 2011, **30**, 4702-4710.
32. Z. Liu, L. Salassa, A. Habtemariam, A. M. Pizarro, G. J. Clarkson and P. J. Sadler, *Inorganic Chemistry*, 2011, **50**, 5777-5783.
33. Z. Liu, A. Habtemariam, A. M. Pizarro, S. A. Fletcher, A. Kisova, O. Vrana, L. Salassa, P. C. A. Bruijninx, G. J. Clarkson, V. Brabec and P. J. Sadler, *J. Med. Chem.*, 2011, **54**, 3011-3026.
34. Y. Geldmacher, K. Splith, I. Kitanovic, H. Alborzinia, S. Can, R. Rubbiani, M. A. Nazif, P. Wefelmeier, A. Prokop, I. Ott, S. Wölfl, I. Neundorf and W. S. Sheldrick, *J. Biol. Inorg. Chem.*, 2012, **17**, 631-646.
35. M. A. Nazif, R. Rubbiani, H. Alborzinia, I. Kitanovic, S. Wölfl, I. Ott and W. S. Sheldrick, *Dalton Trans.*, 2012, **41**, 5587-5598.
36. N. P. E. Barry and P. J. Sadler, *Chem. Soc. Rev.*, 2012, **41**, 3264-3279.
37. R. Payne, P. Govender, B. Therrien, C. M. Clavel, P. J. Dyson and G. S. Smith, *J. Organomet. Chem.*, 2013, **729**, 20-27.
38. M. U. Raja, J. Tauchman, B. Therrien, G. Süß-Fink, T. Riedel and P. J. Dyson, *Inorg. Chim. Acta*, 2014, **409**, 479-483.
39. L. C. Sudding, R. Payne, P. Govender, F. Edefe, C. M. Clavel, P. J. Dyson, B. Therrien and G. S. Smith, *J. Organomet. Chem.*, 2014, **774**, 79-85.
40. V. Novohradsky, Z. Liu, M. Vojtiskova, P. J. Sadler, V. Brabec and J. Kasparkova, *Metallomics*, 2014, **6**, 682-690.
41. F. Kühlwein, K. Polborn and W. Beck, *Z. Anorg. Allg. Chem.*, 1997, **623**, 1211-1219.
42. Y. Nakamura, K. Isobe, H. Morita, S. Yamazaki and S. Kawaguchi, *Inorganic Chemistry*, 1972, **11**, 1573-1578.
43. Z. Liu, I. Romero-Canelón, A. Habtemariam, G. J. Clarkson and P. J. Sadler, *Organometallics*, 2014, **33**, 5324-5333.
44. K. Nakamoto, *Infrared and Raman Spectra of Inorganic and Coordination Compounds: Part B: Applications in Coordination, Organometallic, and Bioinorganic Chemistry*, John Wiley & Sons, Inc., 2008.
45. R. Wanke, P. Smoleński, M. F. C. Guedes Da Silvan, L. M. D. R. S. Martins and A. J. L. Pombeiro, *Inorganic Chemistry*, 2008, **47**, 10158-10168.
46. A. Dorcier, W. H. Ang, S. Bolano, L. Gonsalvi, L. Juillerat-Jeannerat, G. Laurency, M. Peruzzini, A. D. Phillips, F. Zanobini and P. J. Dyson, *Organometallics*, 2006, **25**, 4090-4096.
47. M. Erlandsson, V. R. Landaeta, L. Gonsalvi, M. Peruzzini, A. D. Phillips, P. J. Dyson and G. Laurency, *Eur. J. Inorg. Chem.*, 2008, DOI: 10.1002/ejic.200700792, 620-627.
48. S. Bolaño, M. Plaza, J. Bravo, J. Castro, M. Peruzzini, L. Gonsalvi, G. Ciancaleoni and A. Macchioni, *Inorg. Chim. Acta*, 2010, **363**, 509-516.
49. R. Pettinari, C. Pettinari, F. Marchetti, M. Monari, E. Mosconi and F. De Angelis, *Organometallics*, 2013, **32**, 3895-3902.
50. E. Carmona, A. Cingolani, F. Marchetti, C. Pettinari, R. Pettinari, B. W. Skelton and A. H. White, *Organometallics*, 2003, **22**, 2820-2826.
51. C. Scolaro, A. Bergamo, L. Brescacin, R. Delfino, M. Cocchietto, G. Laurency, T. J. Geldbach, G. Sava and P. J. Dyson, *J. Med. Chem.*, 2005, **48**, 4161-4171.
52. M. Schmidlehner, V. Pichler, A. Roller, M. A. Jakupec, W. Kandioller and B. K. Keppler, *J. Organomet. Chem.*, 2015, **782**, 69-76.
53. W. Kandioller, E. Balsano, S. M. Meier, U. Jungwirth, S. Göschl, A. Roller, M. A. Jakupec, W. Berger, B. K. Keppler and C. G. Hartinger, *Chem. Commun.*, 2013, **49**, 3348-3350.
54. J. Ruiz, V. Rodríguez, N. Cutillas, K. G. Samper, M. Capdevila, Ò. Palacios and A. Espinosa, *Dalton Trans.*, 2012, **41**, 12847-12856.
55. O. Dömötör, S. Aicher, M. Schmidlehner, M. S. Novak, A. Roller, M. A. Jakupec, W. Kandioller, C. G. Hartinger, B. K. Keppler and É. A. Enyedy, *J. Inorg. Biochem.*, 2014, **134**, 57-65.
56. V. Novohradsky, L. Zerzankova, J. Stepankova, A. Kisova, H. Kostrhunova, Z. Liu, P. J. Sadler, J. Kasparkova and V. Brabec, *Metallomics*, 2014, **6**, 1491-1501.
57. A. J. Millett, A. Habtemariam, I. Romero-Canelón, G. J. Clarkson and P. J. Sadler, *Organometallics*, 2015, **34**, 2683-2694.
58. Z. Liu, I. Romero-Canelón, B. Qamar, J. M. Hearn, A. Habtemariam, N. P. E. Barry, A. M. Pizarro, G. J. Clarkson and P. J. Sadler, *Angew. Chem. Int. Ed.*, 2014, **53**, 3941-3946.
59. J. M. Hearn, I. Romero-Canelón, B. Qamar, Z. Liu, I. Hands-Portman and P. J. Sadler, *ACS Chem. Biol.*, 2013, **8**, 1335-1343.
60. E. Ferrari, F. Pignedoli, C. Imbriano, G. Marverti, V. Basile, E. Venturi and M. Saladini, *J. Med. Chem.*, 2011, **54**, 8066-8077.
61. D. K. Rao, H. Liu, S. V. Ambudkar and M. Mayer, *J. BIOL. CHEM.*, 2014, **289**, 31397-31410.

Journal Name

ARTICLE

62. A. Casini, F. EDAFE, M. Erlandsson, L. Gonsalvi, A. Ciancetta, N. Re, A. Ienco, L. Messori, M. Peruzzini and P. J. Dyson, *Dalton Trans.*, 2010, **39**, 5556-5563.
63. A. J. M. Duisenberg, L. M. J. Kroon-Batenburg and A. M. M. Schreurs, *J. Appl. Crystallog.*, 2003, **36**, 220-229.
64. R. H. Blessing, *Acta Crystallogr A*, 1995, **51**, Pt 1/.
65. G. M. Sheldrick, *Acta Crystallogr A*, 2007, **64**, 112-122.
66. K. Mikkelsen and S. O. Nielsen, *Journal of Physical Chemistry*, 1960, **64**, 632-637.

Graphical and textual abstract

Novel Rhodium(III) and Iridium(III) cyclopentadienyl complexes containing curcumin and bisdemethoxycurcumin ligands have been prepared and, for the first time, structurally characterized. The complexes show moderate cytotoxicity to human ovarian carcinoma (A2780 and A2780cisR) cells and also to non-tumorigenic human embryonic kidney (HEK293) cells.

